How the FDA Regulates Peptides
The FDA regulates peptide therapies through the same framework it uses for all drugs and biological products. When a pharmaceutical company develops a new peptide drug, it must go through the full drug approval process - preclinical testing, Phase 1-3 clinical trials, and New Drug Application (NDA) or Biologics License Application (BLA) review. This process typically takes 10-15 years and costs hundreds of millions of dollars. Active pharmaceutical ingredients that complete this process appear in FDA-approved finished products with defined dosing, contraindications, and labeling.
Several peptide active pharmaceutical ingredients have finished products that received full FDA approval. Semaglutide is approved as a finished product for type 2 diabetes and chronic weight management. Tirzepatide is approved as a finished product for the same indications. Other peptide active ingredients used as compounded preparations have not undergone the same finished-product approval process, and the compounded preparation itself is not an FDA-approved finished product.
Many compounded preparations used in clinical practice have not individually gone through the FDA approval process for the compounded preparation - not because they are unsafe, but because the approval process is designed for finished products with commercial exclusivity. Compounded preparations are prepared under a separate regulatory framework (Section 503A or 503B) and dispensed under physician supervision.
Compounding Pharmacy Regulations
Compounding pharmacies operate under a specific regulatory framework that allows them to prepare customized medications, including peptides, under the supervision of a pharmacist. There are two primary regulatory categories for compounding pharmacies under the Federal Food, Drug, and Cosmetic Act.
Section 503A pharmacies prepare compounded medications in response to individual patient prescriptions from licensed physicians. These pharmacies are primarily regulated by state boards of pharmacy and must meet state-specific quality standards. They compound medications on a patient-by-patient basis and cannot distribute products across state lines without state-level agreements.
Section 503B pharmacies - also called outsourcing facilities - are registered with and inspected by the FDA. They follow current Good Manufacturing Practices (cGMP), conduct sterility and potency testing, and can distribute compounded products in larger quantities. These facilities undergo regular FDA inspections and are held to higher manufacturing standards than 503A pharmacies. The Pep Club partners with pharmacies that meet or exceed these regulatory standards to ensure our patients receive safe, accurately dosed medications.
Understanding Peptide Regulatory Categories
Callout
Compounded preparations used in clinical practice fall into several regulatory categories that patients should understand. FDA-approved finished products have completed the full approval process and have defined labeling, approved indications, and post-market surveillance. These represent the highest level of regulatory oversight and evidence support.
Compounded preparations are prepared by licensed pharmacies using bulk pharmaceutical ingredients. When the active pharmaceutical ingredient is also available as an FDA-approved finished product (as with semaglutide and tirzepatide), compounding pharmacies can prepare compounded versions under certain conditions - typically when there are documented shortages or when the compounded version offers a clinically meaningful difference (such as a different dosage form or strength). The regulatory landscape around compounding of commercially available APIs is complex and evolving.
Some compounded preparations - including injectable glutathione and NAD+ - exist in a category where the active ingredient has clinical-use history and pharmacy compounding has been a long-standing practice, but there is no FDA-approved finished product for the same indication. These preparations are available through licensed compounding pharmacies and can be prescribed by physicians exercising their clinical judgment, but patients should understand the regulatory framing differs from FDA-approved finished products.
Recent Regulatory Developments
The regulatory landscape for peptides has been evolving significantly. The FDA has been reviewing its approach to compounded peptides, particularly regarding which bulk drug substances can be used in compounding. The agency maintains a list of substances that can be used in compounding (the "bulks" list) and has been evaluating specific peptides for inclusion or exclusion from this list.
These regulatory changes affect the availability of certain compounded peptides. When the FDA determines that a peptide should not be on the bulks list, compounding pharmacies may no longer be able to prepare it. Conversely, inclusion on the bulks list confirms that a substance can be compounded under the appropriate regulatory framework. Patients should be aware that the availability of specific compounded peptides may change as regulatory reviews are completed.
The Pep Club stays current with all regulatory developments and adjusts our product offerings accordingly. If a regulatory change affects a peptide you are currently using, your physician will proactively contact you to discuss alternative treatment options. We only offer peptides that are legally available through properly licensed compounding pharmacies in full compliance with current federal and state regulations.
What This Means for Patients
Understanding the regulatory framework helps patients make informed decisions about peptide therapy. When your physician recommends a specific peptide, ask about its regulatory status - is it FDA-approved for your indication, FDA-approved for a different indication (off-label use), or a compounded product? Each category carries different levels of evidence and oversight, and understanding where your treatment falls helps you participate meaningfully in treatment decisions.
Patients should know their rights and protections. You have the right to know which pharmacy is preparing your medication, to receive information about the peptide's regulatory status, to understand the evidence supporting its use, and to be informed of any regulatory changes that affect your treatment. A responsible provider like The Pep Club proactively shares this information without patients having to request it.
The most important protection patients have is working with a licensed physician who prescribes based on clinical evidence and medical judgment, and a licensed pharmacy that compounds under regulatory oversight. This combination of medical expertise and pharmaceutical quality control provides a safety framework that unregulated peptide sales simply cannot match. If a provider or supplier cannot clearly explain the regulatory basis for the products they offer, that is a significant red flag.
Avoiding Unregulated Products
Safety note
Interest in compounded preparations has led to a proliferation of unregulated peptide products sold online and marketed for non-medical use. These products are not manufactured under pharmaceutical standards, not tested for human safety, and not subject to regulatory oversight. Independent testing of grey-market peptides has repeatedly found contamination, incorrect potency, and even entirely wrong compounds.
Red flags that indicate an unregulated source include: no prescription required, products labeled "not for human consumption," no pharmacy license displayed, prices significantly below market rates, no physician consultation offered, products shipped from overseas without proper import controls, and payment accepted only via cryptocurrency or wire transfer.
Legitimate compounded therapy always involves a licensed physician consultation, a valid prescription, and dispensing from a licensed compounding pharmacy. At The Pep Club, every step of the process - from medical evaluation to prescription to pharmacy fulfillment - occurs within the regulated healthcare system. This is not a marketing distinction; it is a fundamental safety requirement. Patients who obtain medications outside this framework accept significant and unnecessary health risks.
Frequently asked
Are all peptide therapies FDA-approved?
No. Some peptides - like semaglutide and tirzepatide - have full FDA approval for specific indications. Others are available through compounding pharmacies under a separate regulatory framework. Your physician will explain the regulatory status of any recommended peptide and what that means for the available evidence supporting its use.
Is it legal to get compounded peptides?
Yes. Compounded peptides prescribed by a licensed physician and prepared by a licensed compounding pharmacy are legal. The compounding pharmacy must operate under applicable federal (Section 503A or 503B) and state regulations. The Pep Club works exclusively with properly licensed pharmacies.
Why are some peptides available in other countries but not the US?
Different countries have different regulatory agencies and approval processes. Some peptide active ingredients that are approved in other countries have not completed the FDA approval process in the US. This does not necessarily mean such an active ingredient is unsafe - it may reflect commercial decisions rather than safety concerns. However, it does mean the US evidence standard has not been met for those finished products. The Pep Club catalog is narrowed to compounded preparations of APIs with established US clinical-use history.
What happens if the FDA changes the rules about a peptide I am taking?
If a regulatory change affects a peptide you are currently prescribed, your Pep Club physician will contact you proactively to discuss alternatives. We continuously monitor FDA regulatory updates and ensure all products we offer comply with current regulations. Your treatment continuity and safety are our priorities.